LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Singular Genomics to Present at Cowen’s 43rd Annual Health Care Conference

February 23, 2023 | Last Trade: US$19.85 0.04 -0.20

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at Cowen’s 43rd Annual Health Care Conference in Boston, Massachusetts.

Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, March 7, 2023, at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com, in the News & Events section.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Investor Contact

Matt Clawson
949-370-8500
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact

Dan Budwick, 1AB
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page